Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: Findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group

Annals of Oncology

Volumn 19, Issue 2, 2008, Pages 299-307

  Del Mastro, Lucia ^a   Dozin, B ^a   Aitini, E ^b   Catzeddu, T ^a   Baldini, E ^c   Contu, A ^d   Durando, A ^e   Danese, S ^e   Cavazzini, G ^b   Canavese, G ^a   Bruzzi, P ^a   Pronzato, P ^a   Venturini, M ^a   Porcile, G ^f   Testore, F ^g   Mascia, V ^h   De Fraia, E ^h   Botta, M ⁱ   Merlano, M ^j   Mencoboni, M ^k   Campora, E ^l   Brema, F ^m   Lavarello, A ⁿ   Campogrande, M ^e   Caroti, C ^o   Falcone, A ^p   Banducci, S ^q   Villa, E ^q   Aldighetti, D ^q   Danova, M ^r   Folco, U ^s   Cortesi, E ^t   D'Auria, G ^t   Olmeo, N ^d   Pazzola, A ^d   Mustacchi, G ^u   Dellach, C ^u   more..

^a UNIVERSITY OF GENOA   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

^c SANTA CHIARA HOSPITAL   (Italy)

^d SS Annunziata Hospital   (Italy)

^e Osp S Anna di Torino   (Italy)

^f Ospedale S Lazzaro   (Italy)

^g Ospedale Civile   (Italy)

^h Ospedale Oncologico 'G Businso'   (Italy)

ⁱ Ospedale S Spirito Casale Monferrato   (Italy)

^j S CROCE E CARLE HOSPITAL   (Italy)

^k Osp Civile di Sampierdarena   (Italy)

^l Ospedale Civile   (Italy)

^m San Paolo Hospital   (Italy)

ⁿ Ospedale Sestri   (Italy)

^o GALLIERA HOSPITAL   (Italy)

^p Istituto Toscano Tumori   (Italy)

^q A MANZONI HOSPITAL   (Italy)

^r FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^s Ospedale S Carona   (Italy)

^t POLICLINICO UMBERTO I   (Italy)

^u Centro Oncologico   (Italy)

more..

Author keywords

Adjuvant therapy; Breast cancer; Chemotherapy; Tamoxifen; Timing

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

EID: 38849201677     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm475     Document Type: Article

References (17)

1. li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003; 21: 28-34.
2. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
3. Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 2005; 23: 3686-3696.
4. Colleoni M, Li S, Gelber RD et al, Timing of CMF chemotherapy in combination with tamoxifen in post-menopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol 2005; 16: 716-725.
5. Osborne CK. Interactions of tamoxifen with cytotoxic chemotherapy for breast cancer. In Jordan VC (ed): Long Term Tamoxifen for Breast Cancer. Madison, WI: University of Wisconsin Press 1994; 181-198.
6. Pico C, Martin M, Jara C et al. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: Randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study, Ann Oncol 2004; 15: 79-87.
7. Sertoli MR, Pronzato P, Venturini M et al. A randomized study of concurrent versus sequential adjuvant chemotherapy and tamoxifen in stage II breast cancer. Proc Am Soc Clin Oncol 2002; 21: 46a (Abstr 182).
8. Albain KS, Green SJ, Ravdin PM et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 2002; 21: 37a (Abstr 143).
9. Venturini M, Del Mastro L, Aitini E et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: Results from a randomized trial. J Natl Cancer Inst 2005; 97: 1724-1733.
10. Venturini M, Del Mastro L, Durando A et al. First results of cooperative MIG5 study, a randomized trial in node positive early breast cancer patients. Ann Oncol 2006; 17 (Suppl 11): Xl15 (Abstr A42).
11. Cuzick J. Forest plots and the interpretation of subgroups. Lancet 2005; 365: 1308.
12. Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 2000; 19: 2595-2609.
13. National comprehensive cancer network clinical practice guidelines in oncology Breast Cancer, Version 1.2007 http://www.nccn.org/professiona/ physician_gls/PDF/breast.prd (15 February 2007, date last accessed).
14. Earty Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005; 365: 1687-1717.
15. Albain K, Green S, Osborne K et al. Tamoxifen (I) versus cyclophosphamide, adriamycin and 5-FU plus either concurrent or sequential T in post-menopausal receptor (+), node (+) breast cancer: A Southwest Oncology Group phase III intergroup trial (SWOG-8814-INT0100). Proc Am Soc Clin Oncol 1997; 16: 128a (Abstr 450).
16. French Adjuvanl Study Group. Benefit of high-dose epirubicin regimen in adjuvant chemotherapy for node positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 602-611.
17. Aebi S, Gelber R, Castiglione-Gertsch M et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000; 355: 1869-4874.